Allied Market Research
Loading...
Cart
0

Global Beta-lactam and Beta-lactamase Inhibitors Market Expected to Reach $34,170 Million by 2028

 

Report Code : A05062

quote increase in demand for antimicrobial resistance medication play a major role in the growth of the beta-lactam and beta-lactamase inhibitor market. Furthermore, rise in prevalence of chronic diseases is expected to boost the market growth in the coming years. quote

According to Onkar Sumant
Manager, Healthcare at Allied Market Research

Get 20% Free Customization In This Report
Follow us on Social Media:       
 

According to a new report published by Allied Market Research, titled, "Beta-lactam and Beta-lactamase Inhibitor Market by Drug Class, Disease, and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2019-2028," The global beta-lactam and beta-lactamase inhibitors market size was $27,126 million in 2018, and is projected to reach $34,170 million by 2028, growing at a CAGR of 2.3% from 2019 to 2028. The cephalosporin segment accounted more than two-fifths of the total beta-lactam and beta-lactamase inhibitors market share in 2018.

Beta-lactam and beta-lactamase inhibitors are chemical compounds of natural or semi-synthetic or synthetic origin. They inhibit the growth of bacteria and protozoans. The beta-lactam and beta-lactamase inhibitors market is expected to exhibit significant growth during the forecast period due to increased consumption in low and middle-income countries (LMICs) and rise in prevalence of infectious diseases. In addition, development of novel approaches for new beta-lactam and beta-lactamase inhibitors for treating bacterial infections and a large number of clinical trials, further supplement the market growth.

The beta-lactam and beta-lactamase inhibitors market is expected to exhibit significant growth during the forecast period due to the increased consumption in low- and middle-income countries (LMICs) and rise in prevalence of infectious diseases. In addition, development of novel approaches for new beta-lactam and beta-lactamase inhibitors for treating bacterial infections and a large number of clinical trials further drive the market growth. However, development of antibiotic resistance, driven by misuse of beta-lactam and beta-lactamase inhibitors and the time taken for the regulatory approval is projected to impede the market growth. On the contrary, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant profitable opportunities for the market players.

Based on drug class, the market is categorized into penicillin, cephalosporin, carbapenem, monobactam, and combination. Combination segment is further categorized into penicillin/beta lactamase inhibitors, cephalosporins/beta lactamase inhibitors, and carbapenems/beta lactamase inhibitors. The combination segment is projected to exhibit the highest growth during the forecast period. This is attributed to rise in the prevalence of antimicrobial resistance and increasing incidences of chronic diseases.

Asia-Pacific was the leading revenue contributor to the global beta-lactam and beta-lactamase inhibitors market in 2018, and is expected to remain dominant throughout the forecast period. This is attributed to upsurge in incidence of chronic diseases, increase in geriatric population, rise in consumption of antibiotics, and availability of drugs over-the-counter without prescription.

The report provides a comprehensive analysis of the key players operating in the global beta-lactam and beta-lactamase inhibitors market industry, namely, Abbott Laboratories, Allergan Plc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co. Inc., Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd. The other players in the value chain include Hikma Pharmaceuticals, Melinta Therapeutics, Eli Lilly and Company, Shionogi, Inc., AstraZeneca plc, and others.

Key Findings of the Beta-lactam and Beta-lactamase Inhibitor Market :

  • Based on drug class, cephalosporin segment was the major revenue contributor in 2018 and is anticipated to continue this trend during the forecast period.
  • Based on disease segment, its complicated intra-abdominal infection (cIAI) is expected to exhibit the highest CAGR with 4.8% during the forecast period.
  • Depending on route of administration, the oral segment was the largest revenue contributor in 2018 and expected to continue this trend from 2019 to 2028.
  • U.S. generated the highest revenue in the global beta-lactam and beta-lactamase inhibitors in 2018, accounting more than one-fifth of the global market in 2018.
  • LAMEA is estimated to grow at a highest CAGR during the forecast period.

Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1(855) 550-5975

pr-det-phone help@alliedmarketresearch.com

 

For Media Inquiries, Please Contact

Ram D
Communications Officer
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at
media@alliedmarketresearch.com

 
 

First time buyer?
Check offers and discount on this report
To get this report

 
Click Here
 
 

quote Beta-lactam and Beta-lactamase Inhibitors Market by Drug Class (Penicillin, Cephalosporin, Carbapenem, Monobactam, and Combination), Disease (Urinary Tract Infection, Respiratory Infection, Skin Infection, Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Nosocomial Pneumonia, Blood Stream Infection, and Other Diseases), and Route of Administration (Oral, Intravenous, and Other Route of Administrations): Global Opportunity Analysis and Industry Forecast, 2019–2028 quote

View Report
 
 
Avenue Video Loading...

Avenue: Entire Library membership of Allied Market Research Reports at your disposal

  • Avenue is an innovative subscription-based online report database.
  • Avail an online access to the entire library of syndicated reports on more than 2,000 niche industries and company profiles on more than 12,000 firms across 11 domains.
  • A cost-effective model tailored for entrepreneurs, investors, and students & researchers at universities.
  • Request customizations, suggest new reports, and avail analyst support as per your requirements.
  • Get an access to the library of reports at any time from any device and anywhere.

 
 

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time of readers

 

Featured Readings

 
 

Get Fresh content delivered

Get insights on topics that matter to your business. Stay updated on the area that interests you.

 
Get Industry Data Alerts
 

Buy Full Version
"Global Beta-lactam and Beta-lactamase Inhibitors Market"
Purchase Enquiry